Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jukka Westerbacka

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 16, 2019
Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING StudyJeremy Pettus, Ronan Roussel, Fang Liz Zhou, et al.
Diabetes, Obesity & Metabolism|October 25, 2019
Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT studyAlice Cheng, Stewart Harris, Francesco Giorgino, et al.
Diabetes, Obesity & Metabolism|April 4, 2020
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trialMartin Haluzík, Alice Cheng, Dirk Müller-Wieland, et al.
Diabetes, Obesity & Metabolism|July 3, 2019
Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3)Timothy S Bailey, Jasmanda Wu, Fang L Zhou, et al.
Journal of Lipid Research|October 19, 2004
A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractionsMartin Adiels, Chris Packard, Muriel J Caslake, et al.
Lipids in Health and Disease|September 15, 2012
Expression of ceramide-metabolising enzymes in subcutaneous and intra-abdominal human adipose tissueMaria Kolak, Joanna Gertow, Jukka Westerbacka, et al.
Diabetes, Obesity & Metabolism|May 31, 2019
Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world studySean D Sullivan, Charlie J Nicholls, Rishab A Gupta, et al.
Clinical Endocrinology|February 17, 2007
Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesityDeborah J Wake, Magnus Strand, Eva Rask, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 23, 2011
Dual metabolic defects are required to produce hypertriglyceridemia in obese subjectsMarja-Riitta Taskinen, Martin Adiels, Jukka Westerbacka, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|April 5, 2008
Gene expression in human NAFLDDario Greco, Anna Kotronen, Jukka Westerbacka, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 16, 2019
Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING StudyJeremy Pettus, Ronan Roussel, Fang Liz Zhou, et al.
Diabetes, Obesity & Metabolism|October 25, 2019
Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT studyAlice Cheng, Stewart Harris, Francesco Giorgino, et al.
Diabetes, Obesity & Metabolism|April 4, 2020
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trialMartin Haluzík, Alice Cheng, Dirk Müller-Wieland, et al.
Diabetes, Obesity & Metabolism|July 3, 2019
Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3)Timothy S Bailey, Jasmanda Wu, Fang L Zhou, et al.
Journal of Lipid Research|October 19, 2004
A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractionsMartin Adiels, Chris Packard, Muriel J Caslake, et al.
Lipids in Health and Disease|September 15, 2012
Expression of ceramide-metabolising enzymes in subcutaneous and intra-abdominal human adipose tissueMaria Kolak, Joanna Gertow, Jukka Westerbacka, et al.
Diabetes, Obesity & Metabolism|May 31, 2019
Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world studySean D Sullivan, Charlie J Nicholls, Rishab A Gupta, et al.
Clinical Endocrinology|February 17, 2007
Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesityDeborah J Wake, Magnus Strand, Eva Rask, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 23, 2011
Dual metabolic defects are required to produce hypertriglyceridemia in obese subjectsMarja-Riitta Taskinen, Martin Adiels, Jukka Westerbacka, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|April 5, 2008
Gene expression in human NAFLDDario Greco, Anna Kotronen, Jukka Westerbacka, et al.
Pageof 6